Development and validation of glycolysis-related prognostic score for prediction of prognosis and chemosensitivity of pancreatic ductal adenocarcinoma

© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd..

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with aggressive biological behaviour. Its rapid proliferation and tumour growth require reprogramming of glucose metabolism or the Warburg effect. However, the association between glycolysis-related genes with clinical features and prognosis of PDAC is still unknown. Here, we used the meta-analysis to correlate the hazard ratios (HR) of 106 glycolysis genes from MSigDB by the cox proportional hazards regression analysis in 6 clinical data sets of PDAC patients to form a training cohort, and a single group of PDAC patients from the TCGA, ICGC, Arrayexpress and GEO databases to form the validation cohort. Then, a glycolysis-related prognosis (GRP) score based on 29 glycolysis prognostic genes was established in 757 PDAC patients from the training composite cohort and validated in 267 ICGC-CA validation cohort (all P < .05). In addition, including PADC, the prognostic value was also confirmed in other 7 out of 30 pan-cancer cohorts. The GRP score was significantly related to specific metabolism pathways, immune genes and immune cells in the patients with PADC (all P < .05). Finally, by combining with immune cells, the GRP score also well-predicted the chemosensitivity of patients with PADC in the TCGA cohort (AUC = 0.709). In conclusion, this study developed a GRP score for patients with PDAC in predicting prognosis and chemosensitivity for PDAC.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:25

Enthalten in:

Journal of cellular and molecular medicine - 25(2021), 12 vom: 02. Juni, Seite 5615-5627

Sprache:

Englisch

Beteiligte Personen:

Zhang, Xiu-Ping [VerfasserIn]
Chen, Qinjunjie [VerfasserIn]
Liu, Qu [VerfasserIn]
Wang, Yang [VerfasserIn]
Wang, Fei [VerfasserIn]
Zhao, Zhi-Ming [VerfasserIn]
Zhao, Guo-Dong [VerfasserIn]
Lau, Wan Yee [VerfasserIn]
Gao, Yu-Zhen [VerfasserIn]
Liu, Rong [VerfasserIn]

Links:

Volltext

Themen:

Antineoplastic Agents
Biomarkers, Tumor
Chemosensitivity
Glycolysis
Journal Article
Pancreatic ductal adenocarcinoma
Prognosis
Score
Validation Study

Anmerkungen:

Date Completed 01.10.2021

Date Revised 11.11.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1111/jcmm.16573

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM324954980